Cirius Therapeutics, a clinical stage pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and metabolic diseases, announced today that it will present preclinical data supporting the importance of the unique mechanism of action of its lead drug candidate for NASH at The International Liver Congress
SAN DIEGO and KALAMAZOO, Mich., March 27, 2019 /PRNewswire/ -- Cirius Therapeutics, a clinical stage pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and metabolic diseases, announced today that it will present preclinical data supporting the importance of the unique mechanism of action of its lead drug candidate for NASH at The International Liver Congress™ 2019, occurring in Vienna, Austria, from April 10-14, 2019, at the Reed Messe Wien Exhibition & Congress Center. The presentations are as follows: Title: Effect on MSDC-0602K treatment on the metabolome of a diet-induced murine model. (Abstract FRI-289) Title: MSDC-0602K, a PPAR-gamma sparing modulator of the mitochondrial pyruvate carrier, improves NASH outcome in a diet-induced animal model of non-alcoholic steatohepatitis. (Abstract PS-135) Title: MSDC-0602K targets the mitochondrial pyruvate carrier to treat non-alcoholic steatohepatitis. (Abstract SAT-344) About Cirius Therapeutics For more information about Cirius Therapeutics, visit www.ciriustx.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/cirius-therapeutics-to-present-preclinical-data-for-lead-drug-candidate-in-nash-at-the-international-liver-congress-300819108.html SOURCE Cirius Therapeutics |